This site is intended for
Healthcare Providers Only

How To Use EXPAREL®

How to use EXPAREL
  • EXPAREL is intended for single-dose administration only
  • EXPAREL should be administered with a 25 gauge or larger bore needle
  • Vials of EXPAREL should be inverted to re-suspend the particles immediately prior to withdrawal from the vial
  • EXPAREL should be used within 4 hours of preparation in a syringe1

Non-Opioid Postsurgical Pain Control, You Control

You Control the Administration

EXPAREL should be injected slowly into soft tissues of the surgical site using a deep tissue administration technique. Aspirate frequently to check for blood and minimize the risk of intravascular injection.1

  • Consider infiltrating above and below the fascia to treat pain that originates from cutting through the musculature and fascia
  • Consider infiltrating into the subcutaneous tissue along the length of the surgical site to treat pain originating from the initial surgical incision

You Control the Volume

The volume of EXPAREL may be expanded with up to 280 mL of preservative-free normal sterile saline to ensure sufficient coverage of larger surgical sites.

  • The recommended dose of EXPAREL is based on the surgical site and the volume required to cover the area
    • The maximum dosage should not exceed 266 mg (one 20 mL vial)

Administration Precautions

  • Do not admix EXPAREL with other drugs prior to administration1
  • When administering lidocaine or other non-bupivacaine based local anesthetics into the surgical site, wait at least 20 minutes before administering EXPAREL1
  • Allow topical antiseptics (e.g., Betadine®) to dry before administering EXPAREL into the same surgical site
  • When administering bupivacaine HCl before EXPAREL, use no more than 50% of the total EXPAREL dose (266 mg) (e.g., 50 mL of 0.25% and 25 mL of 0.5% bupivacaine HCl both equate to a total dose of 125 mg)1

Studies conducted with EXPAREL demonstrated that the most common implantable materials (polypropylene, PTFE, silicone, stainless steel, and titanium) are not affected by the presence of EXPAREL any more than they are by saline. None of the materials studied had an adverse effect on EXPAREL.1

Do Not Interchange with Other Formulations of Bupivacaine

Different formulations of bupivacaine are not bioequivalent, even if the milligram strength is the same. Therefore, it is not possible to convert dosing from any other formulations of bupivacaine to EXPAREL.1

View the reimbursement guide for EXPAREL

Reimbursement Guide

View the reimbursement guide for EXPAREL View


Clinical Studies

Clinical Studies

See the clinical data from the pivotal soft tissue trial for EXPAREL. > More


These are not all of the potential important safety considerations for EXPAREL, please see the full Prescribing Information.

To report an adverse event, e-mail drugsafety@pacira.com or dial 1-855-RX-EXPAREL (1-855-793-9727).

For medical inquiries related to EXPAREL, contact Medical Information at medinfo@pacira.com or 1-855-RX-EXPAREL (1-855-793-9727).

Reference:

  1. EXPAREL [prescribing information]. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; 2011.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.


Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.


Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.


In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for EXPAREL.

EXPAREL® Sign Up


Sign up to receive updates on EXPAREL.

Required*

First name*

Last name*

E-mail*

ZIP code*

Providing the optional information about you below enables us to provide information geared to your needs.

Specialty




Yes, I would like to receive periodic updates about EXPAREL via e-mail. I agree to the Privacy Policy.

Thank you! Your registration is complete.

Sorry. There was an error submitting your request. Please try again at another time.

Sorry. The connection to the server was lost. Please try again at another time.

EXPAREL® E-mail


Required*

Your name:*

Your colleague's name:*

Your colleague's e-mail address:*

To learn about our use of your information and your rights, please consult our Privacy Policy.

Your email has been sent.
Thank you!

The email address you entered was invalid.

Unfortunately, your email could not be sent at this time.